

10 ROSTER

24 APR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **RTSP-0211**

Inventors: **Bennett et al.**

Serial No.: **10/018,445**

Filing Date: **December 13, 2001**

Examiner: **Not Yet Assigned**

Group Art Unit: **Not Yet Assigned**

Title: **Antisense Modulation of Integrin Beta 3 Expression**

"Express Mail" Label No. EV104364905US
Date of Deposit April 24, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Box 2327, Arlington, VA 22202

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

U.S. Patent and Trademark Office
Box 2327
Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
 - () Certification in Accordance with §1.97(e) is set forth below; or
 - () The fee of \$180.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- (XX)** In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)

are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/344,520, filed June 25, 1999, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(xx) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata
Jane Massey Licata
Registration No. 32,257

Date: April 24, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. RTSP-0211	Serial No. 10/018,445
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Bennett et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date December 13, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Akiyama, <i>Integrins in cell adhesion and signaling</i> , <i>Hum. Cell</i> , 1996 , 9:181-186	
	AB	Cheresh, <i>Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells</i> , <i>Cancer Metastasis Rev.</i> , 1991 , 10:3-10	
	AC	Clemetson et al., <i>Integrins and cardiovascular disease</i> , <i>Cell. Mol. Life Sci.</i> , 1998 , 54:502-513	
	AD	Elangbam et al., <i>Cell adhesion molecules--update</i> , <i>Vet. Pathol.</i> , 1997 , 34:61-73	
	AE	Horton, <i>The alpha v beta 3 integrin "vitronectin receptor"</i> , <i>Int. J. Biochem. Cell. Biol.</i> , 1997 , 29:721-725	
	AF	Kato, <i>The biologic and clinical spectrum of Glanzmann's thrombasthenia: implications of integrin alpha IIb beta 3 for its pathogenesis</i> , <i>Crit. Rev. Oncol. Hematol.</i> , 1997 , 26:1-23	
	AG	LaFlamme et al., <i>Integrin cytoplasmic domains as connectors to the cell's signal transduction apparatus</i> , <i>Matrix Biol.</i> , 1997 , 16:153-163	
	AH	Rodan et al., <i>Integrin function in osteoclasts</i> , <i>J. Endocrinol.</i> , 1997 , 154 Suppl:S47-56	
	AI	Ruosahti, <i>Integrins as signaling molecules and targets for tumor therapy</i> , <i>Kidney Int.</i> , 1997 , 51:1413-1417	
	AJ	Shattil, <i>Regulation of platelet anchorage and signaling by integrin alpha IIb beta 3</i> , <i>Thromb. Haemost.</i> , 1993 , 70:224-228	
	AK	Trikha et al., <i>Human prostate carcinoma cells express functional alphaIIb(beta)3 integrin</i> , <i>Cancer Res.</i> , 1996 , 56:5071-5078	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. RTSP-0211	Serial No. 10/018,445
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Bennett et al.	
U.S. Department of Commerce		Filing Date December 3, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AL	Akhtar et al., "Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)", Nucleic Acids Research 1991 19(20):5551-5559	
	AM	Dallabrida et al., "Angiogenesis inhibition in vitro by integrin beta 3 antisense expression", FASEB J. 1998 12(5):A1346	
	AN	Dallabrida et al., "Inhibition of angiogenesis in vitro by integrin beta 3 antisense expression", Blood 1997 90(10):286a	
	AO	Sanghvi Y.S., "Heterocyclic base modifications in nucleic acids and their applications in antisense oligonucleotides", Antisense Research and Application 1999 273-288	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. RTSP-0211	Serial No. 10/018,445
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Bennett et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date December 13, 2001	Group Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA	5,578,704	11/26/1996	Kim et al.	530	388.22
	AB	5,652,109	07/29/1997	Kim et al.	435	7.1
	AC	5,652,110	07/29/1997	Kim et al.	435	7.1
	AD	5,789,573	08/04/1998	Baker et al.	536	24.5
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Country	Translation	
					YES	NO
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
	AW					
	AX					

EXAMINER _____ **DATE CONSIDERED** _____